SAN DIEGO, CA / Washington DC – May 14, 2015 – Pathway Genomics Corporation, a data-driven global healthcare company and global clinical laboratory, today announced that Founder and CEO Jim Plante has been appointed by the U.S. Secretary of Commerce, Penny Pritzker, and U.S. Trade Representative (USTR), Ambassador Michael Froman to the Industry Trade Advisory Committee on Chemicals, Pharmaceuticals, Health and Science Products (ITAC 3).
ITAC advisors provide industry expertise in developing trade policy for the United States and offer valuable input as the Administration advances its international trade agenda to improve economic opportunities for America’s businesses, workers, and consumers.
As a member of ITAC, Mr. Plante will provide the President, through the Commerce Secretary and the Office of the United States Trade Representative (USTR), with detailed policy and technical advice, information, and recommendations regarding trade barriers, negotiation of trade agreements, and implementation of existing trade agreements affecting industry sectors. His term expires February 2018.
Mr. Plante gained his experience in areas of international business by starting several successful companies relating to advanced technologies, biotechnology, and manufacturing. He now serves as Founder, Chairman of the Board, and CEO of Pathway Genomics Corporation, a U.S. based, full service advanced molecular testing laboratory that provides personalized genetic health information to physicians in the United States and over 30 countries worldwide.
“Jim is a pioneer in the development and delivery of advanced genetic testing and health services around the globe,” said Barbara Franklin, former United States Commerce Secretary. “He has firsthand knowledge of how our government policies can both help and hinder US progress as we compete in the global marketplace. As a member of the Committee, Jim’s voice will provide valuable advice to the President, Secretary of Commerce, and Trade Representative.”
About Pathway Genomics Corporation
Since its founding in 2008, Pathway Genomics has become known for its dedication to innovation – making it a leader in the commercial healthcare IT industry. Focusing on providing users with the most validated and personalized healthcare information delivered to any device, the company’s program with IBM Watson is the first of its kind to merge artificial intelligence and deep learning with precision medicine, applicable to both consumers and providers.
Based in San Diego, the company’s CLIA and CAP accredited clinical laboratory provides physicians and their patients in more than 40 different countries with actionable and accurate precision healthcare information to improve, or maintain, health and wellness. Pathway Genomics’ testing services cover a variety of conditions including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com.